Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Mesoblast (MESO) Common Equity (2016 - 2022)

Historic Common Equity for Mesoblast (MESO) over the last 10 years, with Q4 2024 value amounting to $461.3 million.

  • Mesoblast's Common Equity fell 933.09% to $461.3 million in Q4 2024 from the same period last year, while for Dec 2024 it was $461.3 million, marking a year-over-year decrease of 933.09%. This contributed to the annual value of $480.4 million for FY2024, which is 428.09% down from last year.
  • Per Mesoblast's latest filing, its Common Equity stood at $461.3 million for Q4 2024, which was down 933.09% from $480.4 million recorded in Q2 2024.
  • In the past 5 years, Mesoblast's Common Equity ranged from a high of $600.9 million in Q1 2021 and a low of $461.3 million during Q4 2024
  • Its 5-year average for Common Equity is $520.2 million, with a median of $517.1 million in 2022.
  • In the last 5 years, Mesoblast's Common Equity soared by 2318.86% in 2021 and then tumbled by 1450.87% in 2022.
  • Over the past 5 years, Mesoblast's Common Equity (Quarter) stood at $518.7 million in 2020, then rose by 3.23% to $535.5 million in 2021, then decreased by 6.63% to $500.0 million in 2022, then grew by 1.75% to $508.7 million in 2023, then decreased by 9.33% to $461.3 million in 2024.
  • Its Common Equity was $461.3 million in Q4 2024, compared to $480.4 million in Q2 2024 and $508.7 million in Q4 2023.